Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro

Transfusion

Volumn 56, Issue , 2016, Pages S6-S15

  Cap, Andrew P ^a   Pidcoke, Heather F ^a   Keil, Shawn D ^b   Staples, Hilary M ^c   Anantpadma, Manu ^c   Carrion, Ricardo ^c   Davey, Robert A ^c   Frazer Abel, Ashley ^d   Taylor, Audra L ^e   Gonzales, Richard ^b,e   Patterson, Jean L ^c   Goodrich, Raymond P ^b  

^a US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^b Terumo BCT   (United States)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^d NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^e U S ARMY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN; RIBOFLAVIN; VIRUS ANTIGEN;

ANTIBODY TITER; APHERESIS; ARTICLE; BLOOD; BLOOD ANALYSIS; CLINICAL EFFECTIVENESS; COMPLEMENT ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CONVALESCENT PLASMA; CYTOPATHOGENIC EFFECT; EBOLA HEMORRHAGIC FEVER; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; LIMIT OF DETECTION; MACACA FASCICULARIS; NONHUMAN; PLAQUE ASSAY; PLASMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TITRIMETRY; ULTRAVIOLET RADIATION; VERO CELL LINE; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; CHLOROCEBUS AETHIOPS; DISINFECTION; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; PROCEDURES; RADIATION RESPONSE; VIROLOGY;

ANIMALS; BLOOD; CERCOPITHECUS AETHIOPS; DISINFECTION; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MACACA FASCICULARIS; RIBOFLAVIN; ULTRAVIOLET RAYS; VERO CELLS; VIRUS INACTIVATION;

EID: 84961807639     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13393     Document Type: Article

References (39)

1. Factsheet. World Health Organization fact sheet [Internet]. Geneva: World Health Organization; 2015 [cited 2015 Apr 3]. Available from: http://apps.who.int/ebola/en/about-ebola/ebola-factsheet.
2. WHO. World Health Organization Fact Sheet #103 [Internet]. Geneva: World Health Organization; 2015 [cited 2015 Apr 3]. Available from: http://www.who.int/mediacentre/factsheets/fs103/en/.
3. WHO Ebola Response Team, Agua-Agum J, Ariyarajah A, Aylward B, et al., West African Ebola epidemic after one year-slowing but not yet under control. N Engl J Med 2015; 372: 584-7.
4. Mupapa K, Massamba M, Kibadi K, et al., Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179 Suppl 1: S18-23.
5. WHO. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease [Internet]. WHO reference number: WHO/HIS/SDS/2014.8. Geneva: World Health Organization; 2014 [cited 2015 Dec 26]. Available from: http://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/.
6. Katz LM, Tobian AA., Ebola virus disease, transmission risk to laboratory personnel, and pretransfusion testing. Transfusion 2014; 54: 3247-51.
7. Owusu-Ofori AK, Parry C, Bates I., Transfusion-transmitted malaria in countries where malaria is endemic: a review of the literature from sub-Saharan Africa. Clin Infect Dis 2010; 51: 1192-8.
8. Owusu-Ofori AK, Betson M, Parry CM, et al., Transfusion-transmitted malaria in Ghana. Clin Infect Dis 2013; 56: 1735-41.
9. Nagalo BM, Bisseye C, Sanou M, et al., Seroprevalence and incidence of transfusion-transmitted infectious diseases among blood donors from regional blood transfusion centres in Burkina Faso, West Africa. Trop Med Int Health 2012; 17: 247-53.
10. Lyon GM, Mehta AK, Varkey JB, et al., Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014; 371: 2402-9.
11. Laperche S, Francophone African Group for Research in Blood. Multinational assessment of blood-borne virus testing and transfusion safety on the African continent. Transfusion 2013; 53: 816-26.
12. Mundt JM, Rouse L, Van den Bossche J, et al., Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol 2014; 90: 957-64.
13. Cadet J, Decarroz C, Wang SY, et al., Mechanisms and products of photosensitized degradation of nucleic-acids and related model compounds. Isr J Chem 1983; 23: 420-9.
14. Jimenez-Marco T, Riera C, Fisa R, et al., The utility of pathogen inactivation technology: a real-life example of Leishmania infantum inactivation in platelets from a donor with an asymptomatic infection. Blood Transfus 2012; 10: 536-41.
15. Keil SD, Bengrine A, Bowen R, et al., Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment. Transfusion 2015; 55: 1736-44. [Database]
16. Cardo LJ, Rentas FJ, Ketchum L, et al., Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006; 90: 85-91.
17. Rentas F, Harman R, Gomez C, et al., Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model. Transfusion 2007; 47: 240-7.
18. Keil SD, Kiser P, Sullivan JJ, et al., Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfusion 2013; 53: 2278-86.
19. Owusu-Ofori S, Kusi J, Owusu-Ofori A, et al., Treatment of whole blood (WB) with riboflavin and UV light: impact on malaria parasite viability and WB storage. Shock 2015; 44 Suppl 1: 33-8.
20. Ruane PH, Edrich R, Gampp D, et al., Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-85.
21. Vanlandingham DL, Keil SD, Horne KM, et al., Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 2013; 53: 284-90.
22. Tonnetti L, Thorp AM, Reddy HL, et al., Reduction of Leishmania donovani infectivity in whole blood using riboflavin and ultraviolet light. Transfusion 2015; 55: 326-9.
23. Goodrich RP, Gilmour D, Hovenga N, et al., A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009; 49: 1205-16.
24. Owada T, Kaneko M, Matsumoto C, et al., Establishment of culture systems for Genotypes 3 and 4 hepatitis E virus (HEV) obtained from human blood and application of HEV inactivation using a pathogen reduction technology system. Transfusion 2014; 54: 2820-7.
25. Ebihara H, Theriault S, Neumann G, et al., In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis 2007; 196 Suppl 2: S313-22.
26. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animals Resources Commission of Life Sciences, N.R.C. Guide for the care and use of laboratory animals. Washington (DC): National Academy Press; 1996.
27. Harbeck R, Giclas P,. Diagnostic immunology laboratory manual. New York: Ravens Press; 1991.
28. Mancini G, Carbonara AO, Heremans JF., Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965; 2: 235-54.
29. Bockstahler LE, Lytle CD, Stafford JE, et al., Ultraviolet enhanced reactivation of a human virus: effect of delayed infection. Mutat Res 1976; 35: 189-98.
30. Lytle CD, Day RS III, Hellman KB, et al., Infection of UV-irradiated xeroderma pigmentosum fibroblasts by herpes simplex virus: study of capacity and Weigle reactivation. Mutat Res 1976; 36: 257-64.
31. Hellman KB, Lytle CD, Bockstahler LE., Radiation enhanced reactivation of herpes simplex virus: effect of caffeine. Mutat Res 1976; 36: 249-56.
32. Jeeves WP, Rainbow AJ., U.V. enhanced reactivation of U.V.-and gamma-irradiated adenovirus in normal human fibroblasts. Int J Radiat Biol Relat Stud Phys Chem Med 1983; 43: 599-623.
33. Jeeves WP, Rainbow AJ., Gamma-ray-enhanced reactivation of UV-irradiated adenovirus in normal human fibroblasts. Mutat Res 1979; 60: 33-41.
34. Valerie K, Delers A, Bruck C, et al., Activation of human immunodeficiency virus type 1 by DNA damage in human cells. Nature 1988; 333: 78-81.
35. Peeples ME, Bratt MA., UV irradiation analysis of complementation between, and replication of, RNA-negative temperature-sensitive mutants of Newcastle disease virus. J Virol 1982; 41: 965-73.
36. Kumar V, Lockerbie O, Keil SD, et al., Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80: 15-21.
37. Famulok M, Burgstaller P., Selective photoinduced flavin-dependent cleavage of RNA at G-U base pairs and kits therefor. US Patent Office, editor. 1998, Boehringer Mannheim GmbH. p. 13.
38. Ji X, Olinger GG, Aris S, et al., Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol 2005; 86 (Pt 9): 2535-42.
39. McClung H, Seth P, Rawls WE., Quantitation of antibodies to Herpes simplex virus types 1 and 2 by complement-dependent antibody lysis of infected cells. Am J Epidemiol 1976; 104: 181-91.